Study aim: The aim of the present study is to investigate the effect of Q10 on laboratory findings in thalassemia patients treated with Iron chelators. Design: This study is a double-blind parallel clinical trial with a 3-month intervention period, in which people are divided into two groups of 43 people randomly using Randomized Allocation Software. Settings and conduct: This study will be conducted at Shahid Mohammadi Hospital and Aburihan Bandar Abbas Center affiliated with Hormozgan University of Medical Sciences. After explaining the study to the patient and obtaining informed consent, the patients are placed in one group and the treatment begins. At the beginning and at the end of the study (3 months later), 10 cc of blood and urine tests were also performed to check the effectiveness of the treatment. In this study, blinding will be done for participants, personnel, and researchers. In this way, drugs and placebo will be placed in the same packages by a person outside the study. Participants/Inclusion and exclusion criteria: Patients with major and intermedia beta-thalassemia disease; patients who have had a history of taking Iron chelators regularly in the past three months, if they wish to cooperate (consent form will be completed by the parents of the patients for children under 18 years old and the patients themselves for patients over 18 years old). Intervention groups: Group 1) 100 mg of ketones will be given daily for 3 months to thalassemia patients treated with Iron chelators. Group 2) Placebo pill (100mg) which does not contain an interfering agent, was given daily for 3 months to thalassemia patients treated with Iron chelators will be given. Main outcome variables: Determining the effectiveness of intervention after treatment using laboratory parameters (urea, creatinine, GFR, uric acid, pr/cr ratio) Using a biochemistry autoanalyzer device